Showing 4841-4850 of 7317 results for "".
- Seborrheic Dermatitis Linked to Systemic Epithelial Barrier Diseases: Analysishttps://practicaldermatology.com/news/seborrheic-dermatitis-linked-to-systemic-epithelial-barrier-diseases-analysis/2484390/Findings from a new retrospective cohort suggest individuals living with seborrheic dermatitis are more likely to have other epithelial barrier diseases such as rosacea, alopecia areata, and celiac disease. Investigators publish
- FDA Warns Websites Selling Unapproved Botulinum Toxin Productshttps://practicaldermatology.com/news/fda-warns-websites-selling-unapproved-botulinum-toxin-products/2484341/The US Food and Drug Administration (FDA) has issued 18 warning letters to website operators illegally marketing unapproved and misbranded botulinum toxin products for cosmetic and medical use. The enforcement action follows reports of adverse events, including sym
- NICE Recommends First Topical JAK Inhibitor for CHE in England and Waleshttps://practicaldermatology.com/news/nice-recommends-first-topical-jak-inhibitor-for-che-in-england-and-wales/2484333/The National Institute for Health and Care Excellence (NICE) has recommended the reimbursement of Anzupgo® (delgocitinib) cream for adult patients with moderate to severe chronic hand eczema (CHE) who have not responded to,
- FDA Clears Ultherapy PRIME for Skin Laxity on Arms, Abdomenhttps://practicaldermatology.com/news/fda-clears-ultherapy-prime-for-skin-laxity-on-arms-abdomen/2484325/The US Food and Drug Administration (FDA) has cleared Ultherapy PRIME for the treatment of skin laxity on the anterior arms, posterior arms, and abdomen, according to Merz Aesthetics. The device is now FDA-cleared for noninvasive lifting and firming of the face, neck, décolleté, and body.
- FDA Approves Restylane Lyft for Chin Augmentation in Adultshttps://practicaldermatology.com/news/fda-approves-restylane-lyft-for-chin-augmentation-in-adults/2484326/Galderma announced today that the U.S. Food and Drug Administration (FDA) has approved Restylane® Lyft™ with Lidocaine for chin augmentation in adults over 21 with mild-to-moderate chin retrusion.
- Analysis: Fibrotic Skin Diseases Linked to Elevated ASCVD Riskhttps://practicaldermatology.com/news/analysis-fibrotic-skin-diseases-linked-to-elevated-ascvd-risk/2484276/Patients with fibrotic skin diseases may have an elevated risk of atherosclerotic cardiovascular disease (ASCVD), according to new real-world data from the TriNetX platform. The study researchers conducted a retrospective cohort
- Tapinarof Sustains AD Remission for 75+ Days Post-Treatmenthttps://practicaldermatology.com/news/tapinarof-sustains-ad-remission-for-75-days-post-treatment/2484253/New long-term data from the ADORING 3 trial show that tapinarof cream 1% (VTAMA, Organon), a non-steroidal topical aryl hydrocarbon receptor agonist, can sustain low disease activity and pruritus in patients with atopic dermatitis (AD), including children as young
- Study IDs Additional Risk Allele in Allopurinol-Induced Cutaneous Reactions in US Patientshttps://practicaldermatology.com/news/study-ids-additional-risk-allele-in-allopurinol-induced-cutaneous-reactions-in-us-patients/2484235/A recently published genetic association study has identified HLA-A34:02 as an independent allele significantly associated with severe cutaneous adverse reactions (SCARs) to allopurinol in a US-based cohort. Researchers from
- Sarecycline Monotherapy Delivers in Real-World Acne Studyhttps://practicaldermatology.com/news/sarecycline-monotherapy-delivers-in-real-world-acne-study/2484121/A post hoc analysis of the PROSES study found that oral sarecycline monotherapy is as effective as combination therapy with topicals in treating moderate-to-severe acne vulgaris (AV), based on 12-week outcomes from a real-world U.S. cohort presented by Dr. Hilary B
- 487-GEP Test Identifies Optimal Systemic Therapy for ADhttps://practicaldermatology.com/news/487-gep-test-identifies-optimal-systemic-therapy-for-ad/2484115/A 487-gene expression profile (487-GEP) test may help personalize systemic therapy selection for patients with atopic dermatitis (AD), according to results from a prospective, multicenter trial presented by Dr. Jonathan Silverberg et al at the 2025 Fall Clinical De